This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Lev Gerlovin is a speaker during the session titled “Assess Value When Innovating to Establish Greater Benefits Relative to Costs.”
For more information on this event, click here.
As several market-leading PD-(L)1 inhibitors face imminent loss of exclusivity (LoE), the industry confronts a stark reality: technological innovation alone no...
Treatment choice is beneficial for people living with rare diseases (RDs) and competition can drive important economic advantages for payers.
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
CRA is a proud sponsor of the the largest and most established orphan drug & rare disease meeting of its kind across the globe. From cell and gene therapy,...
